Jade Pagkas-Bather, MD
Infectious Disease · Chicago, ILNPI 1831533959
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Every reported general payment came from a single manufacturer, Gilead. 2025 is the largest year on record at $4,810, more than ten times the $17 reported in 2022.
Across 20 payments — averaging $247.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
Across 2 payments — averaging $65,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$130K
What the payments were for
- Consulting fees$2,85058%
- Travel & lodging$1,32727%
- Food & beverage$77516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 20 | $4,952 |
How this compares
$4,952 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 83 | $302,827 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $70,503 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $4,952 | $302,82783 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 infectious disease providers in Illinois.
Other infectious disease in Chicago
- Frank PalellaChicago$987K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- James SullivanChicago$100K
- Gregory HuhnChicago$99K
- Maximo BritoChicago$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.